ICH pre-clinical toxicity study duration guideline is one of 10 guidelines finalized in July.
Executive Summary
ICH PRE-CLINICAL TOXICITY GUIDELINE FINALIZED WITH DIFFERENCES IN DURATION requirements among the ICH regions. The ICH M3 guideline reached Step 4, the final step in harmonization prior to ICH members adopting the guidelines, at the International Conference on Harmonization steering committee meeting July 16 in Brussels. A draft of the guideline, which incorporated regional differences in testing requirements, was issued at a November 1996 steering committee meeting ("The Pink Sheet" Dec. 23, 1996, p. 15).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth